PCE

PCE (phencyclidine-ethyl, eticyclidine, or N-ethyl-1-phenylcyclohexylamine) is a synthetic dissociative anesthetic of the arylcyclohexylamine class, a close structural analog of phencyclidine (PCP) in which the piperidine ring is replaced by an N-ethyl group. PCE is one of the most potent dissociatives in the arylcyclohexylamine family, often described as more potent than PCP itself on a milligram basis, with a similarly intense and psychotomimetic character that demands serious respect and careful dose management.

PCE shares much of PCP's pharmacological profile — potent NMDA receptor antagonism, significant dopamine reuptake inhibition, sigma receptor activity — while the ethyl substitution modifies the pharmacokinetic profile and binding characteristics. Community and historical documentation describes PCE as producing a very intense, PCP-quality dissociation with pronounced stimulant properties and an elevated risk of psychosis and mania at high doses compared to ketamine-class compounds.

PCE occupies a significant historical position as one of the earliest PCP analogs to be systematically characterized, documented in pharmacological literature before the era of modern research chemicals. Its potency and PCP-like character have kept it at the margins of recreational use compared to more approachable ketamine analogs, but it is periodically available and has a dedicated community of experienced dissociative users who seek its particular pharmacological character.